Selected research
Industry Research
Progressive Supranuclear Palsy Industry Research Report 2026
Market perspective
The global Progressive Supranuclear Palsy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Progressive Supranuclear Palsy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Progressive Supranuclear Palsy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Progressive Supranuclear Palsy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Progressive Supranuclear Palsy include Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, Biogen Inc., Bristol Myers Squibb (BMS), AbbVie Inc., Acorda Therapeutics Inc., Teva Pharmaceutical Industries Ltd. and Cortice Biosciences, Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Progressive Supranuclear Palsy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Progressive Supranuclear Palsy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Progressive Supranuclear Palsy Market by Company
Novartis AG
Merck & Co., Inc.
GlaxoSmithKline plc
Biogen Inc.
Bristol Myers Squibb (BMS)
AbbVie Inc.
Acorda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Cortice Biosciences, Inc.
Aton Pharma, Inc.
AlzProtect SAS
AB Science
Progressive Supranuclear Palsy Segment by Type
Late Stage
Clinical Trial
Early Stage
Others
Progressive Supranuclear Palsy Segment by Application
Clinics
Hospitals
Research Institutes
Others
Progressive Supranuclear Palsy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Progressive Supranuclear Palsy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Progressive Supranuclear Palsy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Progressive Supranuclear Palsy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Progressive Supranuclear Palsy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Late Stage
- Clinical Trial
- Early Stage
- Others
Applications
- Clinics
- Hospitals
- Research Institutes
- Others
Companies covered
- Novartis AG
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Biogen Inc.
- Bristol Myers Squibb (BMS)
- AbbVie Inc.
- Acorda Therapeutics Inc.
- Teva Pharmaceutical Industries Ltd.
- Cortice Biosciences, Inc.
- Aton Pharma, Inc.
- AlzProtect SAS
- AB Science
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Progressive Supranuclear Palsy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Late Stage
- 2.2.3 Clinical Trial
- 2.2.4 Early Stage
- 2.2.5 Others
- 2.3 Progressive Supranuclear Palsy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinics
- 2.3.3 Hospitals
- 2.3.4 Research Institutes
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Progressive Supranuclear Palsy Breakdown Data by Type
- 3.1 Global Progressive Supranuclear Palsy Historic Market Size by Type (2021-2026)
- 3.2 Global Progressive Supranuclear Palsy Forecasted Market Size by Type (2027-2032)
4 Progressive Supranuclear Palsy Breakdown Data by Application
- 4.1 Global Progressive Supranuclear Palsy Historic Market Size by Application (2021-2026)
- 4.2 Global Progressive Supranuclear Palsy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Progressive Supranuclear Palsy Market Perspective (2021-2032)
- 5.2 Global Progressive Supranuclear Palsy Growth Trends by Region
- 5.2.1 Global Progressive Supranuclear Palsy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Progressive Supranuclear Palsy Historic Market Size by Region (2021-2026)
- 5.2.3 Progressive Supranuclear Palsy Forecasted Market Size by Region (2027-2032)
- 5.3 Progressive Supranuclear Palsy Market Dynamics
- 5.3.1 Progressive Supranuclear Palsy Industry Trends
- 5.3.2 Progressive Supranuclear Palsy Market Drivers
- 5.3.3 Progressive Supranuclear Palsy Market Challenges
- 5.3.4 Progressive Supranuclear Palsy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Progressive Supranuclear Palsy Players by Revenue
- 6.1.1 Global Top Progressive Supranuclear Palsy Players by Revenue (2021-2026)
- 6.1.2 Global Progressive Supranuclear Palsy Revenue Market Share by Players (2021-2026)
- 6.2 Global Progressive Supranuclear Palsy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Progressive Supranuclear Palsy Head Office and Area Served
- 6.4 Global Progressive Supranuclear Palsy Players, Product Type & Application
- 6.5 Global Progressive Supranuclear Palsy Manufacturers Established Date
- 6.6 Global Progressive Supranuclear Palsy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Progressive Supranuclear Palsy Market Size (2021-2032)
- 7.2 North America Progressive Supranuclear Palsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 7.4 North America Progressive Supranuclear Palsy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Progressive Supranuclear Palsy Market Size (2021-2032)
- 8.2 Europe Progressive Supranuclear Palsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 8.4 Europe Progressive Supranuclear Palsy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Progressive Supranuclear Palsy Market Size (2021-2032)
- 9.2 Asia-Pacific Progressive Supranuclear Palsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Progressive Supranuclear Palsy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Progressive Supranuclear Palsy Market Size (2021-2032)
- 10.2 South America Progressive Supranuclear Palsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 10.4 South America Progressive Supranuclear Palsy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Progressive Supranuclear Palsy Market Size (2021-2032)
- 11.2 Middle East & Africa Progressive Supranuclear Palsy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Progressive Supranuclear Palsy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Progressive Supranuclear Palsy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.1.4 Novartis AG Progressive Supranuclear Palsy Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Merck & Co., Inc.
- 12.2.1 Merck & Co., Inc. Company Information
- 12.2.2 Merck & Co., Inc. Business Overview
- 12.2.3 Merck & Co., Inc. Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.2.4 Merck & Co., Inc. Progressive Supranuclear Palsy Product Portfolio
- 12.2.5 Merck & Co., Inc. Recent Developments
- 12.3 GlaxoSmithKline plc
- 12.3.1 GlaxoSmithKline plc Company Information
- 12.3.2 GlaxoSmithKline plc Business Overview
- 12.3.3 GlaxoSmithKline plc Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.3.4 GlaxoSmithKline plc Progressive Supranuclear Palsy Product Portfolio
- 12.3.5 GlaxoSmithKline plc Recent Developments
- 12.4 Biogen Inc.
- 12.4.1 Biogen Inc. Company Information
- 12.4.2 Biogen Inc. Business Overview
- 12.4.3 Biogen Inc. Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.4.4 Biogen Inc. Progressive Supranuclear Palsy Product Portfolio
- 12.4.5 Biogen Inc. Recent Developments
- 12.5 Bristol Myers Squibb (BMS)
- 12.5.1 Bristol Myers Squibb (BMS) Company Information
- 12.5.2 Bristol Myers Squibb (BMS) Business Overview
- 12.5.3 Bristol Myers Squibb (BMS) Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.5.4 Bristol Myers Squibb (BMS) Progressive Supranuclear Palsy Product Portfolio
- 12.5.5 Bristol Myers Squibb (BMS) Recent Developments
- 12.6 AbbVie Inc.
- 12.6.1 AbbVie Inc. Company Information
- 12.6.2 AbbVie Inc. Business Overview
- 12.6.3 AbbVie Inc. Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.6.4 AbbVie Inc. Progressive Supranuclear Palsy Product Portfolio
- 12.6.5 AbbVie Inc. Recent Developments
- 12.7 Acorda Therapeutics Inc.
- 12.7.1 Acorda Therapeutics Inc. Company Information
- 12.7.2 Acorda Therapeutics Inc. Business Overview
- 12.7.3 Acorda Therapeutics Inc. Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.7.4 Acorda Therapeutics Inc. Progressive Supranuclear Palsy Product Portfolio
- 12.7.5 Acorda Therapeutics Inc. Recent Developments
- 12.8 Teva Pharmaceutical Industries Ltd.
- 12.8.1 Teva Pharmaceutical Industries Ltd. Company Information
- 12.8.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 12.8.3 Teva Pharmaceutical Industries Ltd. Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.8.4 Teva Pharmaceutical Industries Ltd. Progressive Supranuclear Palsy Product Portfolio
- 12.8.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 12.9 Cortice Biosciences, Inc.
- 12.9.1 Cortice Biosciences, Inc. Company Information
- 12.9.2 Cortice Biosciences, Inc. Business Overview
- 12.9.3 Cortice Biosciences, Inc. Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.9.4 Cortice Biosciences, Inc. Progressive Supranuclear Palsy Product Portfolio
- 12.9.5 Cortice Biosciences, Inc. Recent Developments
- 12.10 Aton Pharma, Inc.
- 12.10.1 Aton Pharma, Inc. Company Information
- 12.10.2 Aton Pharma, Inc. Business Overview
- 12.10.3 Aton Pharma, Inc. Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.10.4 Aton Pharma, Inc. Progressive Supranuclear Palsy Product Portfolio
- 12.10.5 Aton Pharma, Inc. Recent Developments
- 12.11 AlzProtect SAS
- 12.11.1 AlzProtect SAS Company Information
- 12.11.2 AlzProtect SAS Business Overview
- 12.11.3 AlzProtect SAS Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.11.4 AlzProtect SAS Progressive Supranuclear Palsy Product Portfolio
- 12.11.5 AlzProtect SAS Recent Developments
- 12.12 AB Science
- 12.12.1 AB Science Company Information
- 12.12.2 AB Science Business Overview
- 12.12.3 AB Science Revenue in Progressive Supranuclear Palsy Business (2021-2026)
- 12.12.4 AB Science Progressive Supranuclear Palsy Product Portfolio
- 12.12.5 AB Science Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst